AssetMark Inc’s Karyopharm Therapeutics KPTI Stock Holding History

AssetMark Inc’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6	Closed	-$2K	–	1366
2020 Q1	$2K	Buy	+6	New	+$1.66K	﹤0.01%	1190

Other funds holding KPTI

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

AssetMark Inc's KPTI Position: Q2 2020 in Review

AssetMark Inc sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 6 shares — an estimated $2K sold.

AssetMark Inc first reported a position in KPTI in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

AssetMark Inc reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
AssetMark Inc sold 6 Karyopharm Therapeutics shares in Q2 2020, an estimated $2K.
AssetMark Inc first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 1 quarter.
AssetMark Inc's Karyopharm Therapeutics position peaked at $2K in Q1 2020.
155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on AssetMark Inc's 13F filing for Q2 2020, filed 11 Aug 2020.